Wuxi Atu Announces Licensing Agreement With Janssen Biotech For Tessa Technology

Wuxi Advanced Therapies, A Wholly Owned Subsidiary Of Wuxi Apptec, Announced A Licensing Agreement With Janssen Biotech, Inc., One Of The Janssen Pharmaceutical Companies Of Johnson & Johnson (Janssen).Under This Agreement, Wuxi Atu Will License To Janssen Its Tessa Technology, A High-Performance System That Can Produce 10 Times More Adeno-Associated Viral (Aav) Vectors Than Traditional Aav Manufacturing Systems. Janssen Will Also Have Access To Work On Wuxi Atu'S Proprietary Clonal Suspension Hek293 Cell Line. This Agreement Was Facilitated By Johnson & Johnson Innovation.Aav Vectors Are Commonly Used For The Delivery Of Gene Therapies To Patients Due To Their Ability To Transduce Numerous Cell And Tissue Types. Wuxi Atu'S Tessa Technology Responds To Industry Demand For Large Scale Aav Manufacturing By Producing Higher Quality Aav Particles More Efficiently. Wuxi Atu Has Also Successfully Scaled Up The Tessa Technology To 200L; This Achieved A 10-Fold Higher Yield And A Significantly Higher Percentage Of Full Aav Capsids, Greatly Reducing Overall Aav Production Costs Compared To Traditional Plasmid-Based Aav Production Systems."We Are Honored That Janssen Selected Wuxi Atu'S Tessa Technology." Said Dr. David Chang, Chief Executive Officer Of Wuxi Advanced Therapies. "We Remain Committed To Improving The Tessa Platform To Produce Faster And More Cost-Effective Aav Products For Patients."As A Contract Testing, Development And Manufacturing Organization (Ctdmo) With Global Operations, Wuxi Atu Will Continue To Enhance Its Capability And Capacity To Help Customers Develop And Deliver Life-Changing Cell And Gene Therapies Faster For Patients In Need.As The Advanced Therapies Business Unit Of Wuxi Apptec, Wuxi Advanced Therapies Is A Contract Testing, Development And Manufacturing Organization (Ctdmo) That Offers Integrated Platforms To Transform The Discovery, Development, Testing, Manufacturing, And Commercialization Of Cell And Gene Therapies.As A Global Company With Operations Across Asia, Europe, And North America, Wuxi Apptec Provides A Broad Portfolio Of R&D And Manufacturing Services That Enable Global Pharmaceutical And Healthcare Industry To Advance Discoveries And Deliver Groundbreaking Treatments To Patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!